comparemela.com
Home
Live Updates
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study : comparemela.com
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%...
Related Keywords
Japan ,
United States ,
Japanese ,
Dan Budwick ,
Raymond Stevens ,
David Dalessio ,
Danielle Keatley ,
Company Annual Report On Form ,
Duke University ,
Nasdaq ,
Division Of Endocrinology ,
Exchange Commission ,
Structure Therapeutics Inc ,
Company Phase ,
Davidd Alessio ,
Tolerability Results ,
Treatment Emergent Adverse Events ,
Obesity Cohort ,
Mixed Model ,
Month Toxicology ,
Investor Relations ,
Oral Metabolic ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Report ,
Markets ,
comparemela.com © 2020. All Rights Reserved.